

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 1 of 2

ATTORNEY DOCKET No.

SERIAL No.

00988/1/US (6794-000053/US)

10/618,288

APPLICANT

Thomas E. Barta, et al.

FILING DATE

GROUP

April 25, 2003

Unknown

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate)

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
56.	FB	WO 00/46221	8/10/00	PCT	C07D 405/42		
57.		WO 00/50396	8/31/00	PCT	C07D 211/66		
58.		WO 00/59874	10/12/20	PCT	C07C 259/06		
59.		WO 00/69819	11/23/20	PCT	C07D 211/16		
60.		WO 00/69821	11/23/00	PCT	C07D 211/66		
61.		WO 00/74681	12/14/00	PCT	A61K 31/451		
62.		WO 02/092588	11/21/02	PCT	C07D 309/08		
63.		WO 03/007930	1/30/03	PCT	A61K 31/166		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig	Examiner's Initials	
64.	FB	Brown, "Synthetic Inhibitors of Matrix Metalloproteinases"; <i>Matrix Metalloproteinases</i> , pp. 243-261 (Academic Press, San Diego, CA, Eds. Park, W.C., & Mecham, R.P., 1998)
65.		Dack, et al., "Preparation of N-hydroxytetrahydropyridylsulfonfylacetamides and related compounds as matrix metalloprotease inhibitors," CA 131:44740 (1999) [CA Plus Accession No. 1999:388166]
66.		Denis, et al., "Matrix metalloproteinase inhibitors: Present achievements and future prospects," <i>Invest New Drugs</i> , 15:175-185 (1997).
67.		Freije, et al., "Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas," <i>J. Biol. Chem.</i> , 269(24), pp. 16766-16773 (1994)
68.		Gearing, et al., "Processing of tumour necrosis factor- α precursor by metalloproteinases," <i>Nature</i> , 370:555-557 (1994).

Examiner:


F Bernhardt

Date Considered:

7/8/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 311408173 US



FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 2 of 2

ATTORNEY DOCKET NO.

SERIAL NO.

00988/1/US (6794-000053/US)

10/618,288

APPLICANT

Thomas E. Barta, et al.

FILING DATE

GROUP

April 25, 2003

Unknown

69.	FB	Gu, et al., "S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death," <i>Science</i> , 297, 1186-1190 (2002)
70.		Hughes, et al., "Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism <i>in situ</i> and <i>in vitro</i> ," <i>Biochem. J.</i> , 305, 799-804 (1995)
71.		Kenyon, et al., "A model of angiogenesis in the mouse cornea," <i>Invest Ophthalmol. Vis. Sci.</i> , 37(8):1625-1632 (1996).
72.		Knight, et al., "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases," <i>FEBS Lett.</i> , 296(3):263-266 (1992).
73.		Kuzmic, et al., "High-throughput screening of enzyme inhibitor: simultaneous determination of tight-binding inhibition constants and enzyme concentration," <i>Anal. Biochem.</i> , 286, 45-50 (2000)
74.		Luckow, et al., "Insect Cell Expression Technology", <i>Protein Engineering: Principles and Practice</i> , pp. 183-218 (John Wiley & Sons, Inc., New York, NY, Edited by J.L. Cleland et al., 1996)
75.		Luckow, et al., "Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in <i>escherichia coli</i> ," <i>J. Virol.</i> , 67(8):4566-4579 (1993)
76.		McClure, et al., "Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases," CA 131:125454 (1999) [CA Plus Accession No. 1999:468334]
77.		McGeehan, et al., "Regulation of tumour necrosis factor- α processing by a metalloproteinase inhibitor," <i>Nature</i> , 370:558-561 (1994).
78.		Mitchell, et al., "Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage," <i>J. Clin. Invest.</i> , 97(3):761-768 (1996).
79.		Rasmussen, et al., "Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat," <i>Pharmacol. Ther.</i> , 75(1):69-75 (1997).
80.		Reboul, et al., "The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes," <i>J. Clin. Invest.</i> , 97(9):2011-2019 (1996).
81.		Schwartz, et al., "Synthetic inhibitors of bacterial and mammalian interstitial collagenases," <i>Prog. In Med. Chem.</i> , 29:271-334 (1992).
82.	↓	Tang, "ADAMTS: a novel family of extracellular matrix proteases," <i>Int'l J. Biochem. Cell Biol.</i> , 33, 33-44 (2001)
83.	FB	Woessner, "The Matrix Metalloproteinase Family," <i>Matrix Metalloproteinases</i> , pp. 1-14 (Academic Press, San Diego, CA, Eds. Parks, W.C. & Mecham, R.P., 1998)
84.	FB	A partial search report from PCT Appl. No. PCT/US03/13123

Examiner:

E Benhard

Date Considered:

7/8/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 1 of 2

ATTORNEY DOCKET NO.

SERIAL NO.

00988/1/US (6794-000053/US)

10/618,288

APPLICANT


Thomas E. Barta, et al.

FILING DATE

April 25, 2003

GROUP

Unknown



U.S. PATENT AND TRADEMARK OFFICE
PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate)
1.	FB	4,595,700	6/17/86	Donald, et al.	514/616	
2.	FB	5,451,676	9/19/95	Whittaker, et al.	546/118	
3.	FB	5,472,978	12/5/95	Baker, et al.	514/443	
4.	FB	5,475,138	12/12/95	Pal, et al.	564/342	
5.	FB	5,932,595	8/3/99	Bender, et al.	514/317	
6.	FB	5,998,412	12/7/99	Broka, et al.	514/250	
7.	FB	5,599,994	2/4/97	Pal, et al.	564/355	
8.	FB	6,013,649	1/11/00	Freskos, et al.	514/237.8	
9.	FB	6,300,514	10/9/01	Takahashi, et al.	560/17	
10.	FB	6,372,758 (including 9/5/01 Office action and 10/25/01 notice of allowance from corresponding Appl. No. 09/884,548)	4/16/02	DeCrescenzo, et al.	514/316	
11.		6,387,931 (withdrawn)	5/14/02	Dack, et al.	514/318	
12.	FB	6,448,250 (including 9/5/01 Office action and 1/29/02 notice of allowance from corresponding Appl. No. 09/499,276)	9/10/02	DeCrescenzo, et al.	514/252	
13.	FB	6,492,367 (including 7/5/02 notice of allowance from corresponding Appl. No. 10/084,713)	12/10/02	DeCrescenzo, et al.	514/252	
14.	FB	6,495,568	12/17/02	Dack, et al.	514/318	
15.		U.S. Appl. No. 09/311,837		Barta, et al.		5/14/99
16.	FB	Allowed U.S. Publ. No. 20030073718	4/17/03	Barta, et al.		11/21/01

Examiner:

FB Einhardt

Date Considered:

7/8/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 3173:9005 US



FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 2 of 2

ATTORNEY DOCKET NO.

00988/1/US (6794-000053/US)

SERIAL NO.

10/618,288

APPLICANT

Thomas E. Barta, et al.

FILING DATE

April 25, 2003

GROUP

Unknown

17.	Allowed Appl. No. 10/142,737 ✓		Freskos, et al.	5/10/02
18.	U.S. Appl. No. ✓ 10/291,983		Freskos, et al.	11/12/02
19.	Appl. No. 10/262,622 (including pending independent claims) ✓ 12/19/02 Office action, and 7/22/03 Office action)	P.F.	DeCrescenzo, et al.	9/30/02
20.	<i>FB</i> Allowed U.S. Publ. No. 20030171404	9/11/03	Barta, et al.	7/12/02

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation/ Yes	No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig	Examiner's Initials	


Examiner:

L Bernhard

Date Considered:

7/8/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET No.	SERIAL No.
00988/1/US (Pfizer Ref. 27378/USA)	10/618,288
APPLICANT	
Thomas E. Barta, et al.	
FILING DATE	GROUP
April 25, 2003	1614

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	FB	6,683,093	1/27/04	Barta, et al.	514/316	11/21/01
2.	FB	6,689,794	2/10/04	Freskos, et al.	514/318	5/10/02
3. (notice of allowance enclosed)	FB	6,800,646, including 11/21/03 notice of allowance	10/5/04	DeCrescenzo, et al.	514/316	9/30/02
4.	FB	6,683,078	1/27/04	Barta, et al.	514/231.5	7/12/02
5. (pending claims and Office action enclosed)		Pending claims and 12/2/04 Office action from U.S. Appl. No. 10/887,490		Buchm et al.		7/8/04
6. (pending claims enclosed)		Pending claims from Appl. No. 10/708,202		McDonald, et al.		11/3/03

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
7.	FB	10/9/03 Search Report and 8/3/04 International Preliminary Examination Report from International Patent Application No. PCT/US03/13123

Examiner:

E Benhardt

Date Considered:

7/8/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 327 050975 US